WVE-007 by Wave Life Sciences: status and timeline

WVE-007

GalNAc-conjugated siRNA targeting INHBE to reduce visceral fat while preserving muscle. Dosed once or twice yearly as add-on to or maintenance after GLP-1 agents.

PilotStage 3 of 5

Phase 2a ongoing; dose escalation and add-on trials with GLP-1 agents planned for 2026.

Updated Jan 2026Checked 10 Oct0 updates this week

Milestones

Next · Phase 2a dose escalation (75–600 mg)

Phase 1 durability through six months2025Complete.
Phase 2a dose escalation (75–600 mg)Target 2026Current milestone.
Six-month efficacy data from expanded cohortsTarget Q2 2026Not yet reached.
Combination and add-on trial dataTarget Q3 2026Not yet reached.

Most important updates

Wave announces WVE-007 Phase 2a: 75–600 mg doses show durable Activin E reductionJan 2026

Upcoming

2026Phase 2a dose escalation (75–600 mg) (next)
Q2 2026Six-month efficacy data from expanded cohorts
Q3 2026Combination and add-on trial data

Current obstacles

Long-term durability at higher dosesSix-month Phase 1 data show durability; whether higher doses sustain effect beyond that or trigger immune tolerance unknown.
Muscle preservation in longer trialsEarly data suggest muscle sparing, but longer trials and combination studies will confirm if WVE-007 truly prevents GLP-1 lean loss.

Physics limits

Lipid metabolism complexityActivin E is one of many obesity drivers; silencing it alone may plateau, requiring combination therapy for further gains.
Variable response by obesity phenotypeOnce-yearly dosing requires stable Activin E suppression; not all obesity subtypes may respond equally to this mechanism.

How it works

3 parts

INHBE silencing

Reduce Activin E production

siRNA directs degradation of INHBE mRNA in liver, lowering circulating Activin E, a hormone promoting visceral fat.

Visceral fat loss

Central adiposity reduction with muscle sparing

Activin E suppression shifts lipid metabolism; visceral fat drops while lean mass is preserved, unlike some GLP-1 agents.

Liver targeting

GalNAc directs siRNA to hepatocytes

N-acetylgalactosamine conjugation delivers siRNA to liver with hepatocyte specificity, enabling infrequent systemic dosing.

Spec sheet

Spec	WVE-007
Proposed dosing	Once or twice yearly^R (reported)
Phase 2a doses tested	75–600 mg^R (reported)
Activin E reduction at day 29	56–85% dose-dependent^R (reported)

^R reported by the company

Update log

1 update

Jan 2026

Major: Wave announces WVE-007 Phase 2a: 75–600 mg doses show durable Activin E reductionPressTest

About Wave Life Sciences

The team behind WVE-007

Wave Life Sciences

RNA medicines, PRISM, ADAR editing, siRNA therapies

Wave develops RNA medicines using its PRISM platform for gene editing, RNA interference, and antisense silencing. Lead programs: WVE-006 (ADAR editing for alpha-1 antitrypsin deficiency) and WVE-007 (siRNA for obesity).

PRISM platform combines RNA editing, splicing, RNAi, and antisense silencing.
WVE-006 is first clinical ADAR therapy; interim data supports accelerated FDA approval path.
WVE-007 twice-yearly siRNA for obesity shows durable weight loss while sparing muscle.

wavelifesciences.com (opens wavelifesciences.com)Company profile →

Headquarters: United States
Status: Public
Valuation: public
Works in: BiotechGene editing & therapy
Coverage: 2 programs · 2 updateslatest 1 Mar 2026checked 10 Oct

Spec

WVE-007

Proposed dosing

Once or twice yearly^R (reported)

Phase 2a doses tested

75–600 mg^R (reported)

Activin E reduction at day 29

56–85% dose-dependent^R (reported)